NEWSMAX @NEWSMAX
Pfizer Inc said on Thursday its vaccine for respiratory syncytial virus (RSV) was effective among older adults in a late-stage study and it plans to file for approval with the U.S. health regulator in the coming months.https://t.co/QHDiSdHnAQ — PolitiTweet.org